Coherus Oncology 
Welcome,         Profile    Billing    Logout  
 13 Products   0 Diseases  13 Products   588 Trials   3242 News 
632 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yusimry (adalimumab-aqvh) / Nanjing King-Friend Bio
ChiCTR2500095973: A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under Fasting Conditions

Not yet recruiting
1
238
 
Each subject received a single subcutaneous injection of the test formulation in the fasting state. Each participant was administered the drug subcutaneously only once.; Each subject received a single subcutaneous injection of the reference preparation in the fasting state. Each participant was administered the drug subcutaneously only once.
Hopeshine-Minsheng Hospital of Xinzheng; Nanjing King-friend Biochemical Pharmaceutical.Co.,Ltd., Sponsor's expenses
Prevent and treat a variety of autoimmune diseases
 
 
Udenyca (pegfilgrastim-cbqv) / Intas
POEM, NCT04662892: An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

Recruiting
N/A
200
US
Pegfilgrastim-Cbqv, Neulasta, pegfilgrastim biosimilar
Coherus Biosciences, Inc., Community Clinical Oncology Research Network, LLC
Febrile Neutropenia, Non-myeloid Malignancy
11/22
12/22
Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG
NCT06708624: Ocular Safety and Usability Study for FYB201 PFS

Completed
4
31
US
FYB201 0.5 mg (0.05 mL of 10 mg/mL), ranibizumab-eqrn
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
08/24
08/24
Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology
TORNADO, ChiCTR2000030877: Efficacy and safety of toripalimab combined with first-line chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma

Recruiting
4
30
China
toripalimab combined with first-line chemotherapy
Huashan hospital , Fudan university ; Huashan hospital, Fudan university, scientific research project supported by enterprise
gastric cancer
 
 
ChiCTR2000029068: Study on Toripalimab combined with chemoradiotherapy for recrrunt or metastatic cervical cancer

Recruiting
4
58
China
toripalimab combined with chemoradiotherapy
The First Affiliated Hospital of Soochow University ; The First Affiliated Hospital of Soochow University, Self-raised
cervical cancer
 
 
ChiCTR2000033603: Toripalimab combined with Cetuximab and FOLFIRI for first-line treatment of metastatic unresectable left side, KRAS/NRAS/BRAF wild-type advanced colorectal cancer: a single-arm, open, multicenter clinical study

Recruiting
4
61
China
Toripalimab combined with Cetuximab and FOLFIRI
Jiangsu Cancer Hospital ; Jiangsu Cancer Hospital, self-financing
Colorectal cancer
 
 
ChiCTR2000037024: Neoadjuvant therapy of Toripalimab plus Axitinib for Von Hipple-Lindau disease associated clear cell renal cell carcinoma: a single-arm, single-center, prospective study

Recruiting
4
20
China
Neoadjuvant therapy of Toripalimab plus Axitinib follow by nephrone-sparing surgery
Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine ; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Self-financing
Von Hippel–Lindau disease
 
 
ChiCTR2100051293: Intervention study on preoperative application of PD-1 monoclonal antibody combined with gemcitabine and paclitaxel (albumin binding type) in the treatment of borderline resectable and locally advanced pancreatic cancer

Recruiting
4
30
China
gemcitabine + Albumin paclitaxel + Toripalimab monoclonal antibody
West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Latitudinal project
pancreatic cancer
 
 
ChiCTR2000038249: Application of Toripalimab combined with TKI in preoperative treatment of patients with advanced renal carcinoma

Recruiting
4
25
China
Toripalimab combined with TKI
SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine ; SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine, Shanghai Junshi Biomedical Technology Co., LTD
Renal cell carcinoma
 
 
ChiCTR2200060671: GEMOX 'chemo holiday' combined with regorafenib and toripalimab for biliary tract cancers with high-risk recurrence after surgery: a multicenter prospective cohort study

Not yet recruiting
4
120
China
① GEMOX: a total of 6 courses of treatment. 1 course of treatment was suspended after every 2 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Capecitabine: a total of 8 courses of treatment.
Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine ; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y202148325), and National Natural Science Foundation of China (81800540, 81827804, and 81802330).
Biliary tract cancers
 
 
ChiCTR2100050060: Clinical study on the safety and efficacy of donafenib tosylate combined with toripalimab injection in first-line/second-line treatment of patients with advanced biliary tract cancer who refuse chemotherapy

Not yet recruiting
4
36
China
Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV ;Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, self-raised
Biliary tract cancer
 
 
ChiCTR2100045556: A multicenter, open-label, randomized controlled clinical trail of PD-1 inhibitor (Toripalimab) combined with TPF chemotherapy for neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma

Recruiting
4
100
China
Toripalimab +Docetaxel + Cisplatin + Fluorouracil ;Docetaxel + Cisplatin + Fluorouracil
Sichuan Cancer Hospital ; Sichuan Cancer Hospital, TopAlliance Biosciences Inc.
Locally advanced head and neck squamous cell carcinoma
 
 
Neoadjuvant PD-1 inhibitor plus chemotherapy for NSCLC, ChiCTR1900024014: neoadjuvant PD-1 inhibitor (Toripalimab) plus chemotherapy in stage Ⅱ-Ⅲ NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.

Recruiting
4
50
China
Toripalimab (240mg, q3w) plus Carboplatin-based chemotherapy
Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University ; Shanghai Pulmonary Hospital of Tongji University, Clinical Research Program of Shanghai Pulmonary Hospital in 2019
non-small cell lung cancer
 
 
ChiCTR2100049493: Donafenib and Toripalimab in combination with transarterial chemoembolization and bronchial arterial chemoinfusion Versus Donafenib and Toripalimab in the treatment of hepatocellular carcinoma with pulmonary metastasis: a randomized controlled trial

Not yet recruiting
4
130
China
TACE、BAI combined with donafinib and triprizumab ;donafinib and triprizumab
Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital ; Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital, self-funded
Hepatocellular carcinoma
 
 
TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Recruiting
4
100
Canada, US
Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin
Coherus Biosciences, Inc.
Nasopharyngeal Cancer Recurrent
12/27
12/27
NCT05291910: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Not yet recruiting
4
70
RoW
Inetetamab, Toripalimab, Albumin-Bound Paclitaxel
Chinese Academy of Medical Sciences
Breast Cancer
12/24
12/25
ChiCTR2200057408: Efficacy and safety of triplizumab combined with gemcitabine and cisplatin in the treatment of urothelial cancer

Recruiting
4
40
China
triplizumab combined with paclitaxel ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe
The Second Hospital of Tianjin Medical University ; The Second Hospital of Tianjin Medical University, tianjinshiqingnianrencaituojugongcheng
Urothelial carcinoma
 
 
ChiCTR2300073731: An single-arm, single-center, observational study of Surufatinib combined with Toripalimab and GEMOX as first-line treatment for advanced intrahepatic cholangiocarcinoma

Not yet recruiting
4
30
China
Surufatinib combined with Toripalimab and GEMOX
Yichang Central People's Hospital; Yichang Central People's Hospital, Investigator self-funded
intrahepatic cholangiocarcinoma
 
 
ChiCTR2400087686: A single arm, prospective phase II clinical study to evaluate the efficacy and safety of retinoic acid capsules combined with toripalimab in the treatment of advanced unresectable or metastatic melanoma

Not yet recruiting
4
41
 
retinoic acid capsules plus toripalimab
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Shandong Liangfu Pharmaceutical Co., Ltd. Guangci Translational Medicine Research and Development Fund
melanoma
 
 
ChiCTR2400085526: A single-arm, open, single-center clinical study: The efficacy and safety of surufatinib and toripalimab combined with gemcitabine and cisplatin in patients with unresectable locally advanced or metastatic cholangiocarcinoma

Recruiting
4
20
 
surufatinib and toripalimab combined with gemcitabine and cisplatin
Shandong Cancer Hospital; Shandong Cancer Hospital, Investigator initiated
Biliary tract cancer
 
 
ChiCTR2500101620: Study on the Efficacy and Safety of Toripalimab Combined with Gemcitabine in Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
4
45
 
Toripalimab combined with Gemcitabine
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Investigator-initiated study
prostate cancer
 
 
2020-004437-20: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

Ongoing
3
519
Europe
Toripalimab, LENVIMA, TAB001 and JS001, Solution for infusion, Capsule, hard, LENVIMA
Shanghai Junshi Biosciences Co., Ltd, Shanghai Junshi Biosciences Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
advanced hepatocellular carcinoma (HCC), liver cancer, Diseases [C] - Cancer [C04]
 
 
JUPITER-02, NCT03581786: The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Hourglass Jan 2023 - Jun 2023 : Approval in US in combination with chemotherapy for 1L nasopharyngeal carcinoma
Checkmark Submitted in UK in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
Nov 2022 - Nov 2022: Submitted in UK in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
Checkmark Submitted in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
Nov 2022 - Nov 2022: Submitted in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
More
Active, not recruiting
3
289
RoW
TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy, Placebos
Shanghai Junshi Bioscience Co., Ltd.
Recurrent or Metastatic NPC
05/20
10/22
Jupiter06, NCT03829969: Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Checkmark Submitted in UK in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Nov 2022 - Nov 2022: Submitted in UK in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Checkmark Submitted in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Nov 2022 - Nov 2022: Submitted in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Checkmark Approved in China in combination with paclitaxel and cisplatin in 1L esophageal squamous cell carcinoma
More
Completed
3
514
RoW
Toripalimab, JS001, TAB001
Shanghai Junshi Bioscience Co., Ltd.
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
03/21
09/23
NCT04376866: Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recruiting
3
204
RoW
Toripalimab, JS001
Cancer Hospital of Guangxi Medical University
Recurrent Nasopharyngeal Carcinoma
04/23
04/28
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Completed
3
421
RoW
Biological : Toripalimab Drug: Axitinib, sunitinib
Shanghai Junshi Bioscience Co., Ltd.
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
04/24
01/25
NCT03924050: Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Recruiting
3
440
RoW
TORIPALIMAB INJECTION(JS001 )
Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer
07/23
08/24
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Recruiting
3
194
RoW
Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI
Hutchison Medipharma Limited
Advanced Neuroendocrine Carcinoma
05/25
05/25
NCT04709380: Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTT

Terminated
3
36
RoW
Radiotherapy plus Toripalimab, Sorafenib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Radiotherapy, Toripalimab, Sorafenib, Advanced Hepatocellular Carcinoma
12/24
02/25
HEPATORCH, NCT04723004: Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Active, not recruiting
3
326
RoW
Toripalimab combined with Bevacizumab, Sorafenib
Shanghai Junshi Bioscience Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
10/23
12/24
NCT05056337: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Enrolling by invitation
3
220
RoW
Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
11/23
12/23
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
3
364
RoW
Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Locally Advanced or Metastatic Urothelial Carcinoma
11/23
11/25
HCHTOG1909, NCT04280822: Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Recruiting
3
400
RoW
Neoadjuvant immunochemotherapy
Henan Cancer Hospital
Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
12/23
03/28
NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Recruiting
3
200
RoW
Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin
Sun Yat-sen University
Hepatocellular Carcinoma
07/25
12/26
NCT06170489: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Recruiting
3
185
RoW
JS004 in combination with Toripalimab, Bendamustine or gemcitabine
Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma
05/25
09/27
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Completed
3
256
RoW
JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
Shanghai Junshi Bioscience Co., Ltd.
Metastatic Melanoma, Unresectable Melanoma
07/23
11/23
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting
3
531
RoW
JS001, Nab-Paclitaxel, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Triple-Negative Breast Cancer
02/25
12/25
NCT04711434: PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Recruiting
3
260
RoW
PD-1 Antibody, Toripalimab
Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Fujian Cancer Hospital, Guangdong Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Kunming Medical College.
Lynch Syndrome
12/23
12/25
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Recruiting
3
264
RoW
Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy
02/29
02/30
Neotorch, NCT04158440: Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Checkmark Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Jan 2023 - Jan 2023: Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Active, not recruiting
3
501
RoW
4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab, Cisplatin;, Carboplatin;, Pemetrexed;, Paclitaxel;, Docetaxel, 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
Shanghai Junshi Bioscience Co., Ltd.
Stage II-III Non-small Cell Lung Cancer
06/25
12/25
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
NCT06228079: Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Recruiting
3
176
RoW
Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen
Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi Zhuang Autonomous Region, Shenzhen Second People's Hospital
Recurrent Nasopharyngeal Carcinoma
06/28
06/28
SCLC, NCT06441344: Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

Not yet recruiting
3
136
NA
Toripalimab plus Anlotinib, Toripalimab
Taizhou Hospital
SCLC, Maintenance Treatment
05/26
05/30
NCT06235203: Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recruiting
3
154
RoW
endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy
Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi Zhuang Autonomous Region, Shenzhen Second People's Hospital
Recurrent Nasopharyngeal Carcinoma
06/27
06/27
NCT06505837: JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Recruiting
3
356
RoW
JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy, JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
06/25
12/26
NCT06561763: TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting
3
416
NA
Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
Sun Yat-sen University
High Risk Locally Advanced Nasopharyngeal Carcinoma
08/28
08/31
NCT06592326: 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting
3
460
RoW
9MW2821, Toripalimab, Toripalimab injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin/Carboplatin, Cisplatin for injection/Carboplatin Injection
Mabwell (Shanghai) Bioscience Co., Ltd.
Urothelial Carcinoma
09/27
12/28
neoR-TORCH, NCT06437977: Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients

Recruiting
3
478
RoW
SBRT, Toripalimab, Toripalimab IV 240mg + platinum-based doublet chemotherapy
Shanghai Chest Hospital
Stage II-III Non-small Cell Lung Cancer
06/27
06/29
JYKQ-2024-105, NCT06647563: Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Not yet recruiting
3
355
NA
Toripalimab, PD-1 antibody, Cetuximab, EGFR antibody, Albumin-Bound Paclitaxel, Carboplatin, Cisplatin, Radiotherapy 60 Gray/day, Radiotherapy 66 Gray/day, Radiotherapy 70 Gray/day
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Squamous Cell Carcinoma of Head and Neck
09/29
09/30
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
3
212
RoW
PD-1 blocking antibody, JS001, GP, IMRT
Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
12/25
12/28
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting
3
212
RoW
Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/27
NCT06712888: Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting
3
466
RoW
TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy, GP plus placebo induction therapy
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Cancer Center, Affiliated Hospital of Guangdong Medical University, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, The University of Hong Kong-Shenzhen Hospital, Hunan Cancer Hospital, The Affiliated Cancer Hosipital of Guizhou Meidical University, Sichuan Cancer Hospital and Research Institute, Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
01/30
01/32
NCT04778956: Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Recruiting
3
218
RoW
Toripalimab, PD-1 antibody, salvage surgery
Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Tenth Affiliated Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma, PD-1, Surgery
03/25
03/33
NEOTORCH-BREAST04, NCT06977893: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study

Recruiting
3
194
RoW
Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy
First Affiliated Hospital of Zhejiang University
HR+/HER2- Breast Cancer
03/27
03/30
NCT04365036: A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Recruiting
3
207
RoW
Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT)
Sun Yat-sen University
NK/T Cell Lymphoma Nos
12/28
12/28
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma

Active, not recruiting
3
540
RoW
PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
05/25
05/27
TD-NEOE3V3, NCT06952621: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

Not yet recruiting
3
390
RoW
3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF）
Tang-Du Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
12/27
12/28
NCT04453813: Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Recruiting
3
226
RoW
Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
07/25
07/27
NCT06026878: GNT Induction Treatment in Locally Advanced NPC

Recruiting
3
228
RoW
gemcitabine,nimotuzumab, toripalimab, GNT, gemcitabine, cisplatin, GP
Air Force Military Medical University, China
Nasopharyngeal Carcinoma
09/25
09/27
NCT05669092: A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Recruiting
3
174
RoW
Toripalimab, PD-1inhibitor, CRT, LCRT, SCRT, short-course radiotherapy, XELIRI, Capecitabine and Irinotecan, FOLFRINOX, Irinotecan,Oxaliplatin and 5-FU
Zhejiang Cancer Hospital
Toripalimab, Radiation
12/25
12/25
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting
3
878
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
06/26
07/28
NCT05869227: Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
166
RoW
Capecitabine/Placebo combined with toripalimab
XIANG YANQUN, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhujiang Hospital
Nasopharyngeal Carcinoma, Maintenance Therapy
12/27
12/27
ChiCTR2100051031: A multicenter, prospective, randomized controlled study of radiotherapy combined with teriprizumab versus radiotherapy alone in the treatment of elderly patients with locally advanced nasopharyngeal carcinoma

Recruiting
3
164
 
Teriprolizumab treatment ;Radiotherapy alone
Jiangxi Cancer Hospital; Jiangxi Cancer Hospital, none
Nasopharyngeal carcinoma
 
 
LungMate-008, NCT04772287: Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC

Not yet recruiting
3
341
NA
Toripalimab, Cisplatin/Carboplatin, Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel, Toripalimab mimetic (placebo)
Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer
12/26
12/27
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Recruiting
3
452
RoW
RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin
RemeGen Co., Ltd.
Urothelial Carcinoma, HER2-expressing
12/26
04/28
ChiCTR2200055494: A randomized, controlled, single-blind, multicenter Phase II/III clinical study of PD-1 inhibitors combined with chemoraotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma

Recruiting
3
154
China
2 cycles of induction chemotherapy + 3 cycles of synchronous chemotherapy + 7 cycles of tiriplizumab immunotherapy ;2 cycles of induction chemotherapy + 3 cycles of synchronous chemotherapy + 7 cycles of placebo
Sichuan Cancer Hospital ; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project
nasopharyngeal carcinoma
 
 
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, not recruiting
3
663
RoW
Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
05/27
05/27
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Recruiting
3
480
RoW
Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin
Shanghai Junshi Bioscience Co., Ltd.
Intrahepatic Cholangiocarcinoma
05/27
05/27
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NCT03992911: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Recruiting
2/3
336
RoW
Simmtecan, 5-FU and l-LV, FOLFSIM regimen, Toripalimab, JS001, Etoposide, Cisplatin, EP regimen, Etoposide, Carboplatin, EC regimen
Peking University
Neuroendocrine Carcinoma of the Bladder
06/22
06/23
NCT05809336: Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Completed
2/3
172
RoW
Inosine 0.2g orally 3 times/day, Camrelizumab for injection, Sintilimab injection, Penpulimab injection, Tislelizumab injection, Pembrolizumab injection, Toripalimab, Atezolizumab, chemotherapy/targeting, PD-1/PD-L1 inhibitor ,chemotherapy/targeting
Beijing Friendship Hospital
Advanced Solid Tumor
10/22
10/22
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/25
12/26
JUPITER 04, NCT03859128: Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Active, not recruiting
2/3
402
RoW
TORIPALIMAB INJECTION(JS001 )
Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma
04/23
08/23
NCT05125055: Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Recruiting
2/3
80
RoW
Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin, Docetaxel, 5-Fluorouracil
Shanghai Jiao Tong University School of Medicine
Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
09/24
12/26
NCT04890522: An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Not yet recruiting
2/3
622
RoW
Triprilimab(JS001), Cisplatin, 5-Fluorouracil, Gemcitabine
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy, Survival
12/23
12/28
NCT05817201: Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Recruiting
2/3
60
RoW
Toripalimab, JS001, TAB001, Tegafur, S-1, IMRT, Irradiation, intensity modulation radiation therapy
Taizhou Hospital
Esophageal Cancer, Radiation Therapy, Immunotherapy, Chemotherapy
12/23
12/24
NCT06984588: A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Recruiting
2/3
450
RoW
Uliledlimab, Toripalimab, Pembrolizumab
TJ Biopharma Co., Ltd.
Non Small Cell Lung Cancer
08/28
09/28
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Recruiting
2/3
130
RoW
RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets
RemeGen Co., Ltd.
Gastric Cancer
07/24
07/25
ChiCTR2300067514: The evaluation of safety and efficacy of GC 'chemo holiday' combined with lenvatinib and toripalimab for unresectable biliary tract cancers

Not yet recruiting
2/3
30
 
(1) GC chemo holiday (2) Lenvatinib (3) Triprilizumab
Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by National Natural Science Foundation of China (81800540, 81827804, and 81802330).
Biliary tract cancers
 
 
NCT04446663: Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2a
50
NA
Toripalimab, JS001, Albumin-bound Paclitaxel, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT
First People's Hospital of Foshan
Nasopharyngeal Neoplasms
12/23
12/24
NCT05342506: Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Not yet recruiting
2a
30
NA
Toripalimab + ScTIL
Peking Union Medical College Hospital, Chineo Medicine (Beijing) Co., Ltd.
Cervical Cancer, Ovarian Cancer, Malignant Trophoblastic Tumor
02/24
05/24
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer

Ongoing
2
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HR-negative, HER2-low breast cancer
 
 
RC48-C026, CTR20232220: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab versus pertuzumab with or without toripalimab in the neoadjuvant treatment of patients with HER2-positive breast cancer

Ongoing
2
80
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, Perjeta (pertuzumab) - Roche
Remegen Biopharmaceutical (Yantai) Co., Ltd
HER2-positive breast cancer
 
 
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g

Recruiting
2
90
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma
 
 
ChiCTR2100049563: A single-arm, phase II study to toripalimab combined with pazopanib in treatment of patients with simple lung metastasis clear cell renal cell carcinoma before operation

Not yet recruiting
2
40
China
Toripalimab combined with pazopanib
Fudan University Shanghai Cancer Center ; Fudan University Shanghai Cancer Center, No
Clear Cell Renal Cell Carcinoma
 
 
NCT06889649: SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Recruiting
2
30
RoW
Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI)
Peking University First Hospital
Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
02/27
02/28
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Active, not recruiting
2
30
RoW
combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
01/20
11/21
NCT04177797: Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Active, not recruiting
2
20
RoW
Toripalimab
Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma
06/20
12/23
NCT04605796: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
2
54
RoW
Toripalimab combined with Bevacizumab
Shanghai Junshi Bioscience Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
12/20
12/22
2019-FXY-020, NCT03854838: IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Active, not recruiting
2
25
RoW
Tolipalimab, JS001, Reirradiation
Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
02/21
02/23
NASCR, NCT03623776: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

Withdrawn
2
80
RoW
JS001, Toripalimab, Pemetrexed, Pemetrexed Disodium, Carboplatin, CBP, Thoracic Surgery
Sun Yat-sen University
Efficacy and Safety
12/25
12/26
NCT04170179: Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis

Recruiting
2
25
RoW
Systemic chemotherapy, Lenvatinib, Toripalimab
Sun Yat-sen University
Hepatocellular Carcinoma
04/21
04/21
ChiCTR1900023710: Toripalimab combined with capecitabine for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy: a prospective, single-arm, phase II trial

Not yet recruiting
2
23
China
Toripalimab combined with capecitabine
Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University ; Sun Yat-sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents six courses of Toripalimab for each patient.
Nasopharyngeal Carcinoma
 
 
ChiCTR2000033668: TACE and Lenvatinib Plus PD-1 Antibody Versus TACE Plus Lenvtinib for Advanced HCC: a Single-Centre Randomised Controlled Trial

Not yet recruiting
2
80
China
TACE+Lenvatinib plus toripalimab, an inhibitor of PD1 ;TACE+Lenvatinib
Eastern Hepatobiliary Surgery Hospital ; Eastern Hepatobiliary Surgery Hospital, Shanghai Junshi Biopharmaceutical Technology Co., Ltd.
Advanced unresectable HCC
 
 
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
128
RoW
neoadjuvant treatment
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital
Cholangiocarcinoma, Intrahepatic
08/21
08/23
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
50
RoW
Bevacizumab, QL1101, Tripleitriumab, JS001
Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd.
Refractory Metastatic Colorectal Cancer, pMMR, MSS
09/21
02/22
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Completed
2
61
RoW
Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib
Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
09/23
09/23
ChiCTR2000031730: Open-label, single-center phase II clinical trial of low-dose dicitabine combined with triplezumab for the treatment of recurrent refractory follicular lymphoma

Recruiting
2
46
China
low-dose dicitabine combined with triplezumab
Cancer Prevention and Treatment Center, Sun Yat-Sen University ; Cancer Prevention and Treatment Center, Sun Yat-Sen University, Unfunded projects
Follicular lymphoma
 
 
ZLJS2019, ChiCTR1900026420: A prospective, open-labelled, phase II clinical trial of neoadjuvant JS001 for resectable non-small cell lung cancer

Not yet recruiting
2
45
 
After 2 cycles of neoadjuvant JS001 (3mg/kg Q2W, ivdrip), all participants will undergo curative resection of lung cancer.
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Junshi Bioscieces
Non-small cell lung cancer
 
 
ChiCTR2000029713: Albumin paclitaxel plus platinum and toripalimab as first-line treatment for recurrent/metastatic head and neck squamous cell carcinaoma: Phase II Clinical Trial

Not yet recruiting
2
37
China
Albumin paclitaxel plus platinum and toripalimab
Shenzhen Hospital of cancer hospital of Chinese Academy of Medical Sciences ; Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Raise independently
Head and neck squamous cell carcinaoma
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yusimry (adalimumab-aqvh) / Nanjing King-Friend Bio
ChiCTR2500095973: A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under Fasting Conditions

Not yet recruiting
1
238
 
Each subject received a single subcutaneous injection of the test formulation in the fasting state. Each participant was administered the drug subcutaneously only once.; Each subject received a single subcutaneous injection of the reference preparation in the fasting state. Each participant was administered the drug subcutaneously only once.
Hopeshine-Minsheng Hospital of Xinzheng; Nanjing King-friend Biochemical Pharmaceutical.Co.,Ltd., Sponsor's expenses
Prevent and treat a variety of autoimmune diseases
 
 
Udenyca (pegfilgrastim-cbqv) / Intas
POEM, NCT04662892: An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

Recruiting
N/A
200
US
Pegfilgrastim-Cbqv, Neulasta, pegfilgrastim biosimilar
Coherus Biosciences, Inc., Community Clinical Oncology Research Network, LLC
Febrile Neutropenia, Non-myeloid Malignancy
11/22
12/22
Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG
NCT06708624: Ocular Safety and Usability Study for FYB201 PFS

Completed
4
31
US
FYB201 0.5 mg (0.05 mL of 10 mg/mL), ranibizumab-eqrn
Formycon AG
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
08/24
08/24
Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology
TORNADO, ChiCTR2000030877: Efficacy and safety of toripalimab combined with first-line chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma

Recruiting
4
30
China
toripalimab combined with first-line chemotherapy
Huashan hospital , Fudan university ; Huashan hospital, Fudan university, scientific research project supported by enterprise
gastric cancer
 
 
ChiCTR2000029068: Study on Toripalimab combined with chemoradiotherapy for recrrunt or metastatic cervical cancer

Recruiting
4
58
China
toripalimab combined with chemoradiotherapy
The First Affiliated Hospital of Soochow University ; The First Affiliated Hospital of Soochow University, Self-raised
cervical cancer
 
 
ChiCTR2000033603: Toripalimab combined with Cetuximab and FOLFIRI for first-line treatment of metastatic unresectable left side, KRAS/NRAS/BRAF wild-type advanced colorectal cancer: a single-arm, open, multicenter clinical study

Recruiting
4
61
China
Toripalimab combined with Cetuximab and FOLFIRI
Jiangsu Cancer Hospital ; Jiangsu Cancer Hospital, self-financing
Colorectal cancer
 
 
ChiCTR2000037024: Neoadjuvant therapy of Toripalimab plus Axitinib for Von Hipple-Lindau disease associated clear cell renal cell carcinoma: a single-arm, single-center, prospective study

Recruiting
4
20
China
Neoadjuvant therapy of Toripalimab plus Axitinib follow by nephrone-sparing surgery
Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine ; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Self-financing
Von Hippel–Lindau disease
 
 
ChiCTR2100051293: Intervention study on preoperative application of PD-1 monoclonal antibody combined with gemcitabine and paclitaxel (albumin binding type) in the treatment of borderline resectable and locally advanced pancreatic cancer

Recruiting
4
30
China
gemcitabine + Albumin paclitaxel + Toripalimab monoclonal antibody
West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Latitudinal project
pancreatic cancer
 
 
ChiCTR2000038249: Application of Toripalimab combined with TKI in preoperative treatment of patients with advanced renal carcinoma

Recruiting
4
25
China
Toripalimab combined with TKI
SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine ; SIR RUN RUN SHAW Hospital affiliated to Zhejiang University School of Medicine, Shanghai Junshi Biomedical Technology Co., LTD
Renal cell carcinoma
 
 
ChiCTR2200060671: GEMOX 'chemo holiday' combined with regorafenib and toripalimab for biliary tract cancers with high-risk recurrence after surgery: a multicenter prospective cohort study

Not yet recruiting
4
120
China
① GEMOX: a total of 6 courses of treatment. 1 course of treatment was suspended after every 2 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Capecitabine: a total of 8 courses of treatment.
Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine ; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y202148325), and National Natural Science Foundation of China (81800540, 81827804, and 81802330).
Biliary tract cancers
 
 
ChiCTR2100050060: Clinical study on the safety and efficacy of donafenib tosylate combined with toripalimab injection in first-line/second-line treatment of patients with advanced biliary tract cancer who refuse chemotherapy

Not yet recruiting
4
36
China
Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV ;Donafenib tablet, 200 mg BID Po; Toripalimab, 240 mg Q3W IV
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences ; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, self-raised
Biliary tract cancer
 
 
ChiCTR2100045556: A multicenter, open-label, randomized controlled clinical trail of PD-1 inhibitor (Toripalimab) combined with TPF chemotherapy for neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma

Recruiting
4
100
China
Toripalimab +Docetaxel + Cisplatin + Fluorouracil ;Docetaxel + Cisplatin + Fluorouracil
Sichuan Cancer Hospital ; Sichuan Cancer Hospital, TopAlliance Biosciences Inc.
Locally advanced head and neck squamous cell carcinoma
 
 
Neoadjuvant PD-1 inhibitor plus chemotherapy for NSCLC, ChiCTR1900024014: neoadjuvant PD-1 inhibitor (Toripalimab) plus chemotherapy in stage Ⅱ-Ⅲ NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.

Recruiting
4
50
China
Toripalimab (240mg, q3w) plus Carboplatin-based chemotherapy
Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University ; Shanghai Pulmonary Hospital of Tongji University, Clinical Research Program of Shanghai Pulmonary Hospital in 2019
non-small cell lung cancer
 
 
ChiCTR2100049493: Donafenib and Toripalimab in combination with transarterial chemoembolization and bronchial arterial chemoinfusion Versus Donafenib and Toripalimab in the treatment of hepatocellular carcinoma with pulmonary metastasis: a randomized controlled trial

Not yet recruiting
4
130
China
TACE、BAI combined with donafinib and triprizumab ;donafinib and triprizumab
Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital ; Department of Interventional Radiology, Chinese People’s Liberation Army General Hospital, self-funded
Hepatocellular carcinoma
 
 
TRANSPARENT, NCT06457503: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Recruiting
4
100
Canada, US
Toripalimab, JS001, TAB-001, CHS-007, Cisplatin, Gemcitabine, Carboplatin
Coherus Biosciences, Inc.
Nasopharyngeal Cancer Recurrent
12/27
12/27
NCT05291910: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Not yet recruiting
4
70
RoW
Inetetamab, Toripalimab, Albumin-Bound Paclitaxel
Chinese Academy of Medical Sciences
Breast Cancer
12/24
12/25
ChiCTR2200057408: Efficacy and safety of triplizumab combined with gemcitabine and cisplatin in the treatment of urothelial cancer

Recruiting
4
40
China
triplizumab combined with paclitaxel ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe ;triplizumab combined with paclitaxe
The Second Hospital of Tianjin Medical University ; The Second Hospital of Tianjin Medical University, tianjinshiqingnianrencaituojugongcheng
Urothelial carcinoma
 
 
ChiCTR2300073731: An single-arm, single-center, observational study of Surufatinib combined with Toripalimab and GEMOX as first-line treatment for advanced intrahepatic cholangiocarcinoma

Not yet recruiting
4
30
China
Surufatinib combined with Toripalimab and GEMOX
Yichang Central People's Hospital; Yichang Central People's Hospital, Investigator self-funded
intrahepatic cholangiocarcinoma
 
 
ChiCTR2400087686: A single arm, prospective phase II clinical study to evaluate the efficacy and safety of retinoic acid capsules combined with toripalimab in the treatment of advanced unresectable or metastatic melanoma

Not yet recruiting
4
41
 
retinoic acid capsules plus toripalimab
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Shandong Liangfu Pharmaceutical Co., Ltd. Guangci Translational Medicine Research and Development Fund
melanoma
 
 
ChiCTR2400085526: A single-arm, open, single-center clinical study: The efficacy and safety of surufatinib and toripalimab combined with gemcitabine and cisplatin in patients with unresectable locally advanced or metastatic cholangiocarcinoma

Recruiting
4
20
 
surufatinib and toripalimab combined with gemcitabine and cisplatin
Shandong Cancer Hospital; Shandong Cancer Hospital, Investigator initiated
Biliary tract cancer
 
 
ChiCTR2500101620: Study on the Efficacy and Safety of Toripalimab Combined with Gemcitabine in Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
4
45
 
Toripalimab combined with Gemcitabine
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Investigator-initiated study
prostate cancer
 
 
2020-004437-20: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

Ongoing
3
519
Europe
Toripalimab, LENVIMA, TAB001 and JS001, Solution for infusion, Capsule, hard, LENVIMA
Shanghai Junshi Biosciences Co., Ltd, Shanghai Junshi Biosciences Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
advanced hepatocellular carcinoma (HCC), liver cancer, Diseases [C] - Cancer [C04]
 
 
JUPITER-02, NCT03581786: The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Hourglass Jan 2023 - Jun 2023 : Approval in US in combination with chemotherapy for 1L nasopharyngeal carcinoma
Checkmark Submitted in UK in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
Nov 2022 - Nov 2022: Submitted in UK in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
Checkmark Submitted in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
Nov 2022 - Nov 2022: Submitted in combination with cisplatin and gemcitabine for 1L locally recurrent or metastatic nasopharyngeal carcinoma
More
Active, not recruiting
3
289
RoW
TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy, Placebos
Shanghai Junshi Bioscience Co., Ltd.
Recurrent or Metastatic NPC
05/20
10/22
Jupiter06, NCT03829969: Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Checkmark Submitted in UK in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Nov 2022 - Nov 2022: Submitted in UK in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Checkmark Submitted in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Nov 2022 - Nov 2022: Submitted in combination with paclitaxel and cisplatin for 1L unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma
Checkmark Approved in China in combination with paclitaxel and cisplatin in 1L esophageal squamous cell carcinoma
More
Completed
3
514
RoW
Toripalimab, JS001, TAB001
Shanghai Junshi Bioscience Co., Ltd.
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
03/21
09/23
NCT04376866: Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recruiting
3
204
RoW
Toripalimab, JS001
Cancer Hospital of Guangxi Medical University
Recurrent Nasopharyngeal Carcinoma
04/23
04/28
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Completed
3
421
RoW
Biological : Toripalimab Drug: Axitinib, sunitinib
Shanghai Junshi Bioscience Co., Ltd.
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
04/24
01/25
NCT03924050: Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Recruiting
3
440
RoW
TORIPALIMAB INJECTION(JS001 )
Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer
07/23
08/24
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Recruiting
3
194
RoW
Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI
Hutchison Medipharma Limited
Advanced Neuroendocrine Carcinoma
05/25
05/25
NCT04709380: Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTT

Terminated
3
36
RoW
Radiotherapy plus Toripalimab, Sorafenib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Radiotherapy, Toripalimab, Sorafenib, Advanced Hepatocellular Carcinoma
12/24
02/25
HEPATORCH, NCT04723004: Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Active, not recruiting
3
326
RoW
Toripalimab combined with Bevacizumab, Sorafenib
Shanghai Junshi Bioscience Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
10/23
12/24
NCT05056337: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Enrolling by invitation
3
220
RoW
Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
11/23
12/23
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting
3
364
RoW
Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Locally Advanced or Metastatic Urothelial Carcinoma
11/23
11/25
HCHTOG1909, NCT04280822: Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Recruiting
3
400
RoW
Neoadjuvant immunochemotherapy
Henan Cancer Hospital
Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
12/23
03/28
NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Recruiting
3
200
RoW
Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin
Sun Yat-sen University
Hepatocellular Carcinoma
07/25
12/26
NCT06170489: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Recruiting
3
185
RoW
JS004 in combination with Toripalimab, Bendamustine or gemcitabine
Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma
05/25
09/27
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Completed
3
256
RoW
JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
Shanghai Junshi Bioscience Co., Ltd.
Metastatic Melanoma, Unresectable Melanoma
07/23
11/23
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting
3
531
RoW
JS001, Nab-Paclitaxel, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Triple-Negative Breast Cancer
02/25
12/25
NCT04711434: PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Recruiting
3
260
RoW
PD-1 Antibody, Toripalimab
Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Fujian Cancer Hospital, Guangdong Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Kunming Medical College.
Lynch Syndrome
12/23
12/25
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Recruiting
3
264
RoW
Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine
Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy
02/29
02/30
Neotorch, NCT04158440: Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Checkmark Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Jan 2023 - Jan 2023: Results from Neotorch trial in combination with platinum-containing doublet chemotherapy for resectable stage II-III NSCLC
Active, not recruiting
3
501
RoW
4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab, Cisplatin;, Carboplatin;, Pemetrexed;, Paclitaxel;, Docetaxel, 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
Shanghai Junshi Bioscience Co., Ltd.
Stage II-III Non-small Cell Lung Cancer
06/25
12/25
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
NCT06228079: Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Recruiting
3
176
RoW
Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen
Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi Zhuang Autonomous Region, Shenzhen Second People's Hospital
Recurrent Nasopharyngeal Carcinoma
06/28
06/28
SCLC, NCT06441344: Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

Not yet recruiting
3
136
NA
Toripalimab plus Anlotinib, Toripalimab
Taizhou Hospital
SCLC, Maintenance Treatment
05/26
05/30
NCT06235203: Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recruiting
3
154
RoW
endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy
Eye & ENT Hospital of Fudan University, Shanghai Zhongshan Hospital, Shanghai 6th People's Hospital, Changhai Hospital, Fujian Medical University Union Hospital, People's Hospital of Guangxi Zhuang Autonomous Region, Shenzhen Second People's Hospital
Recurrent Nasopharyngeal Carcinoma
06/27
06/27
NCT06505837: JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Recruiting
3
356
RoW
JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy, JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
06/25
12/26
NCT06561763: TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting
3
416
NA
Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
Sun Yat-sen University
High Risk Locally Advanced Nasopharyngeal Carcinoma
08/28
08/31
NCT06592326: 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting
3
460
RoW
9MW2821, Toripalimab, Toripalimab injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin/Carboplatin, Cisplatin for injection/Carboplatin Injection
Mabwell (Shanghai) Bioscience Co., Ltd.
Urothelial Carcinoma
09/27
12/28
neoR-TORCH, NCT06437977: Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients

Recruiting
3
478
RoW
SBRT, Toripalimab, Toripalimab IV 240mg + platinum-based doublet chemotherapy
Shanghai Chest Hospital
Stage II-III Non-small Cell Lung Cancer
06/27
06/29
JYKQ-2024-105, NCT06647563: Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Not yet recruiting
3
355
NA
Toripalimab, PD-1 antibody, Cetuximab, EGFR antibody, Albumin-Bound Paclitaxel, Carboplatin, Cisplatin, Radiotherapy 60 Gray/day, Radiotherapy 66 Gray/day, Radiotherapy 70 Gray/day
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Squamous Cell Carcinoma of Head and Neck
09/29
09/30
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
3
212
RoW
PD-1 blocking antibody, JS001, GP, IMRT
Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
12/25
12/28
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting
3
212
RoW
Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/27
NCT06712888: Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting
3
466
RoW
TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy, GP plus placebo induction therapy
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Cancer Center, Affiliated Hospital of Guangdong Medical University, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, The University of Hong Kong-Shenzhen Hospital, Hunan Cancer Hospital, The Affiliated Cancer Hosipital of Guizhou Meidical University, Sichuan Cancer Hospital and Research Institute, Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
01/30
01/32
NCT04778956: Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Recruiting
3
218
RoW
Toripalimab, PD-1 antibody, salvage surgery
Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Tenth Affiliated Hospital, Sun Yat-sen University
Nasopharyngeal Carcinoma, PD-1, Surgery
03/25
03/33
NEOTORCH-BREAST04, NCT06977893: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study

Recruiting
3
194
RoW
Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy
First Affiliated Hospital of Zhejiang University
HR+/HER2- Breast Cancer
03/27
03/30
NCT04365036: A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Recruiting
3
207
RoW
Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT)
Sun Yat-sen University
NK/T Cell Lymphoma Nos
12/28
12/28
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma

Active, not recruiting
3
540
RoW
PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
05/25
05/27
TD-NEOE3V3, NCT06952621: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

Not yet recruiting
3
390
RoW
3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF）
Tang-Du Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
12/27
12/28
NCT04453813: Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Recruiting
3
226
RoW
Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy
Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
07/25
07/27
NCT06026878: GNT Induction Treatment in Locally Advanced NPC

Recruiting
3
228
RoW
gemcitabine,nimotuzumab, toripalimab, GNT, gemcitabine, cisplatin, GP
Air Force Military Medical University, China
Nasopharyngeal Carcinoma
09/25
09/27
NCT05669092: A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Recruiting
3
174
RoW
Toripalimab, PD-1inhibitor, CRT, LCRT, SCRT, short-course radiotherapy, XELIRI, Capecitabine and Irinotecan, FOLFRINOX, Irinotecan,Oxaliplatin and 5-FU
Zhejiang Cancer Hospital
Toripalimab, Radiation
12/25
12/25
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting
3
878
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
06/26
07/28
NCT05869227: Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
166
RoW
Capecitabine/Placebo combined with toripalimab
XIANG YANQUN, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhujiang Hospital
Nasopharyngeal Carcinoma, Maintenance Therapy
12/27
12/27
ChiCTR2100051031: A multicenter, prospective, randomized controlled study of radiotherapy combined with teriprizumab versus radiotherapy alone in the treatment of elderly patients with locally advanced nasopharyngeal carcinoma

Recruiting
3
164
 
Teriprolizumab treatment ;Radiotherapy alone
Jiangxi Cancer Hospital; Jiangxi Cancer Hospital, none
Nasopharyngeal carcinoma
 
 
LungMate-008, NCT04772287: Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC

Not yet recruiting
3
341
NA
Toripalimab, Cisplatin/Carboplatin, Pemetrexed (non-squamous cell carcinoma)/ Docetaxel/ Gemcitabine/ Vinorelbine/ Paclitaxel, Toripalimab mimetic (placebo)
Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer
12/26
12/27
RC48-C016, NCT05302284: A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Recruiting
3
452
RoW
RC48-ADC, Disitamab Vedotin, Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin
RemeGen Co., Ltd.
Urothelial Carcinoma, HER2-expressing
12/26
04/28
ChiCTR2200055494: A randomized, controlled, single-blind, multicenter Phase II/III clinical study of PD-1 inhibitors combined with chemoraotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma

Recruiting
3
154
China
2 cycles of induction chemotherapy + 3 cycles of synchronous chemotherapy + 7 cycles of tiriplizumab immunotherapy ;2 cycles of induction chemotherapy + 3 cycles of synchronous chemotherapy + 7 cycles of placebo
Sichuan Cancer Hospital ; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project
nasopharyngeal carcinoma
 
 
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, not recruiting
3
663
RoW
Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel
Shanghai Junshi Bioscience Co., Ltd.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
05/27
05/27
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Recruiting
3
480
RoW
Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin
Shanghai Junshi Bioscience Co., Ltd.
Intrahepatic Cholangiocarcinoma
05/27
05/27
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NCT03992911: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Recruiting
2/3
336
RoW
Simmtecan, 5-FU and l-LV, FOLFSIM regimen, Toripalimab, JS001, Etoposide, Cisplatin, EP regimen, Etoposide, Carboplatin, EC regimen
Peking University
Neuroendocrine Carcinoma of the Bladder
06/22
06/23
NCT05809336: Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Completed
2/3
172
RoW
Inosine 0.2g orally 3 times/day, Camrelizumab for injection, Sintilimab injection, Penpulimab injection, Tislelizumab injection, Pembrolizumab injection, Toripalimab, Atezolizumab, chemotherapy/targeting, PD-1/PD-L1 inhibitor ,chemotherapy/targeting
Beijing Friendship Hospital
Advanced Solid Tumor
10/22
10/22
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/25
12/26
JUPITER 04, NCT03859128: Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Active, not recruiting
2/3
402
RoW
TORIPALIMAB INJECTION(JS001 )
Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma
04/23
08/23
NCT05125055: Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Recruiting
2/3
80
RoW
Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin, Docetaxel, 5-Fluorouracil
Shanghai Jiao Tong University School of Medicine
Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
09/24
12/26
NCT04890522: An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Not yet recruiting
2/3
622
RoW
Triprilimab(JS001), Cisplatin, 5-Fluorouracil, Gemcitabine
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy, Survival
12/23
12/28
NCT05817201: Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Recruiting
2/3
60
RoW
Toripalimab, JS001, TAB001, Tegafur, S-1, IMRT, Irradiation, intensity modulation radiation therapy
Taizhou Hospital
Esophageal Cancer, Radiation Therapy, Immunotherapy, Chemotherapy
12/23
12/24
NCT06984588: A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Recruiting
2/3
450
RoW
Uliledlimab, Toripalimab, Pembrolizumab
TJ Biopharma Co., Ltd.
Non Small Cell Lung Cancer
08/28
09/28
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Recruiting
2/3
130
RoW
RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets
RemeGen Co., Ltd.
Gastric Cancer
07/24
07/25
ChiCTR2300067514: The evaluation of safety and efficacy of GC 'chemo holiday' combined with lenvatinib and toripalimab for unresectable biliary tract cancers

Not yet recruiting
2/3
30
 
(1) GC chemo holiday (2) Lenvatinib (3) Triprilizumab
Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by National Natural Science Foundation of China (81800540, 81827804, and 81802330).
Biliary tract cancers
 
 
NCT04446663: Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2a
50
NA
Toripalimab, JS001, Albumin-bound Paclitaxel, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT
First People's Hospital of Foshan
Nasopharyngeal Neoplasms
12/23
12/24
NCT05342506: Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Not yet recruiting
2a
30
NA
Toripalimab + ScTIL
Peking Union Medical College Hospital, Chineo Medicine (Beijing) Co., Ltd.
Cervical Cancer, Ovarian Cancer, Malignant Trophoblastic Tumor
02/24
05/24
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer

Ongoing
2
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HR-negative, HER2-low breast cancer
 
 
RC48-C026, CTR20232220: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab versus pertuzumab with or without toripalimab in the neoadjuvant treatment of patients with HER2-positive breast cancer

Ongoing
2
80
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, Perjeta (pertuzumab) - Roche
Remegen Biopharmaceutical (Yantai) Co., Ltd
HER2-positive breast cancer
 
 
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g

Recruiting
2
90
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma
 
 
ChiCTR2100049563: A single-arm, phase II study to toripalimab combined with pazopanib in treatment of patients with simple lung metastasis clear cell renal cell carcinoma before operation

Not yet recruiting
2
40
China
Toripalimab combined with pazopanib
Fudan University Shanghai Cancer Center ; Fudan University Shanghai Cancer Center, No
Clear Cell Renal Cell Carcinoma
 
 
NCT06889649: SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Recruiting
2
30
RoW
Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI)
Peking University First Hospital
Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
02/27
02/28
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Active, not recruiting
2
30
RoW
combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
01/20
11/21
NCT04177797: Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Active, not recruiting
2
20
RoW
Toripalimab
Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma
06/20
12/23
NCT04605796: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
2
54
RoW
Toripalimab combined with Bevacizumab
Shanghai Junshi Bioscience Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
12/20
12/22
2019-FXY-020, NCT03854838: IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Active, not recruiting
2
25
RoW
Tolipalimab, JS001, Reirradiation
Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
02/21
02/23
NASCR, NCT03623776: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

Withdrawn
2
80
RoW
JS001, Toripalimab, Pemetrexed, Pemetrexed Disodium, Carboplatin, CBP, Thoracic Surgery
Sun Yat-sen University
Efficacy and Safety
12/25
12/26
NCT04170179: Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis

Recruiting
2
25
RoW
Systemic chemotherapy, Lenvatinib, Toripalimab
Sun Yat-sen University
Hepatocellular Carcinoma
04/21
04/21
ChiCTR1900023710: Toripalimab combined with capecitabine for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy: a prospective, single-arm, phase II trial

Not yet recruiting
2
23
China
Toripalimab combined with capecitabine
Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University ; Sun Yat-sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents six courses of Toripalimab for each patient.
Nasopharyngeal Carcinoma
 
 
ChiCTR2000033668: TACE and Lenvatinib Plus PD-1 Antibody Versus TACE Plus Lenvtinib for Advanced HCC: a Single-Centre Randomised Controlled Trial

Not yet recruiting
2
80
China
TACE+Lenvatinib plus toripalimab, an inhibitor of PD1 ;TACE+Lenvatinib
Eastern Hepatobiliary Surgery Hospital ; Eastern Hepatobiliary Surgery Hospital, Shanghai Junshi Biopharmaceutical Technology Co., Ltd.
Advanced unresectable HCC
 
 
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
128
RoW
neoadjuvant treatment
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital
Cholangiocarcinoma, Intrahepatic
08/21
08/23
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
50
RoW
Bevacizumab, QL1101, Tripleitriumab, JS001
Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd.
Refractory Metastatic Colorectal Cancer, pMMR, MSS
09/21
02/22
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Completed
2
61
RoW
Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib
Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
09/23
09/23
ChiCTR2000031730: Open-label, single-center phase II clinical trial of low-dose dicitabine combined with triplezumab for the treatment of recurrent refractory follicular lymphoma

Recruiting
2
46
China
low-dose dicitabine combined with triplezumab
Cancer Prevention and Treatment Center, Sun Yat-Sen University ; Cancer Prevention and Treatment Center, Sun Yat-Sen University, Unfunded projects
Follicular lymphoma
 
 
ZLJS2019, ChiCTR1900026420: A prospective, open-labelled, phase II clinical trial of neoadjuvant JS001 for resectable non-small cell lung cancer

Not yet recruiting
2
45
 
After 2 cycles of neoadjuvant JS001 (3mg/kg Q2W, ivdrip), all participants will undergo curative resection of lung cancer.
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Junshi Bioscieces
Non-small cell lung cancer
 
 
ChiCTR2000029713: Albumin paclitaxel plus platinum and toripalimab as first-line treatment for recurrent/metastatic head and neck squamous cell carcinaoma: Phase II Clinical Trial

Not yet recruiting
2
37
China
Albumin paclitaxel plus platinum and toripalimab
Shenzhen Hospital of cancer hospital of Chinese Academy of Medical Sciences ; Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Raise independently
Head and neck squamous cell carcinaoma
 
 
 

Download Options